Variation in germination of Clostridium difficile clinical isolates correlates to disease severity

Anaerobe

Volumn 33, Issue , 2015, Pages 64-70

  Carlson, Paul E ^a   Kaiser, Alyssa M ^a   McColm, Sarah A ^a   Bauer, Jessica M ^a   Young, Vincent B ^a   Aronoff, David M ^b   Hanna, Philip C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; Germination; NAP1 027; Ribotype; Spore

Indexed keywords

GLYCINE; HISTIDINE; TAUROCHOLIC ACID;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; IN VITRO STUDY; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; SPORE GERMINATION; BACTERIAL SPORE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

CLOSTRIDIUM DIFFICILE;

CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; SEVERITY OF ILLNESS INDEX; SPORES, BACTERIAL;

EID: 84922748691     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2015.02.003     Document Type: Article

References (35)

1. Dubberke E. Clostridium difficile infection: the scope of the problem. J.Hosp. Med. 2012, 7(Suppl.3):S1-S4.
2. Kuijper E.J., Coignard B., Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 2006, 12(Suppl.6):2-18.
3. Britton R.A., Young V.B. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 2014, 146:1547-1553.
4. Britton R.A., Young V.B. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 2012, 20:313-319.
5. Dubberke E.R., Wertheimer A.I. Review of current literature on the economic burden of Clostridium difficile infection. Infect. Control Hosp. Epidemiol. 2009, 30:57-66.
6. Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 2009, 7:526-536.
7. Gerding D.N., Muto C.A., Owens R.C. Measures to control and prevent Clostridium difficile infection. Clinical infectious diseases : an official publication of the infectious diseases society of America 2008, 46(Suppl.1):S43-S49.
8. Burns D.A., Heap J.T., Minton N.P. Clostridium difficile spore germination: an update. Res. Microbiol. 2010, 161:730-734.
9. Paredes-Sabja D., Shen A., Sorg J.A. Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol. 2014, 22:406-416.
10. Sorg J.A., Sonenshein A.L. Bile salts and glycine as cogerminants for Clostridium difficile spores. J.Bacteriol. 2008, 190:2505-2512.
11. Wheeldon L.J., Worthington T., Lambert P.A. Histidine acts as a co-germinant with glycine and taurocholate for Clostridium difficile spores. J.Appl. Microbiol. 2011, 110(4):987-994.
12. Moore P., Kyne L., Martin A., Solomon K. Germination efficiency of clinical Clostridium difficile spores and correlation with ribotype, disease severity and therapy failure. J.Med. Microbiol. 2013, 62:1405-1413.
13. Heeg D., Burns D.A., Cartman S.T., Minton N.P. Spores of Clostridium difficile clinical isolates display a diverse germination response to bile salts. PLoS One 2012, 7:e32381.
14. Rao K., Walk S.T., Micic D., Chenoweth E., Deng L., Galecki A.T., et al. Procalcitonin levels associate with severity of Clostridium difficile infection. PLoS One 2013, 8:e58265.
15. Walk S.T., Micic D., Jain R., Lo E.S., Trivedi I., Liu E.W., et al. Clostridium difficile Ribotype Does Not Predict Severe Infection. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America 2012, vol. 55:1661-1668.
16. Sorg J.A., Dineen S.S. Laboratory maintenance of Clostridium difficile. Curr. Protoc. Microbiol. 2009, (Chapter 9):Unit 9A.1.
17. Carlson P.E., Walk S.T., Bourgis A.E., Liu M.W., Kopliku F., Lo E., et al. The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates. Anaerobe 2013, 24:109-116.
18. McDonald L.C., Coignard B., Dubberke E., Song X., Horan T., Kutty P.K. Recommendations for surveillance of Clostridium difficile-associated disease. Infect. Control Hosp. Epidemiol. 2007, 28:140-145.
19. Cartman S.T., Heap J.T., Kuehne S.A., Cockayne A., Minton N.P. The emergence of 'hypervirulence' in Clostridium difficile. Int. J. Med. Microbiol. 2010, 300:387-395.
20. Razavi B., Apisarnthanarak A., Mundy L.M. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection 2007, 35:300-307.
21. Merrigan M., Venugopal A., Mallozzi M., Roxas B., Viswanathan V.K., Johnson S., et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J.Bacteriol. 2010, 192:4904-4911.
22. Chen J.W., Scaria J., Mao C., Sobral B., Zhang S., Lawley T., et al. Proteomic comparison of historic and recently emerged hypervirulent Clostridium difficile strains. J.Proteome Res. 2013, 12:1151-1161.
23. Lanis J.M., Hightower L.D., Shen A., Ballard J.D. TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing. Mol. Microbiol. 2012, 84:66-76.
24. Dawson L.F., Valiente E., Donahue E.H., Birchenough G., Wren B.W. Hypervirulent Clostridium difficile PCR-ribotypes exhibit resistance to widely used disinfectants. PLoS One 2011, 6:e25754.
25. Valiente E., Dawson L.F., Cairns M.D., Stabler R.A., Wren B.W. Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage. J.Med. Microbiol. 2012, 61:49-56.
26. Cookson B. Hypervirulent strains of Clostridium difficile. Postgrad. Med. J. 2007, 83:291-295.
27. Valiente E., Cairns M.D., Wren B.W. The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move. Clin. Microbiol. Infect. 2014, 20:396-404.
28. Kuijper E.J., van Dissel J.T., Wilcox M.H. Clostridium difficile: changing epidemiology and new treatment options. Curr. Opin. Infect. Dis. 2007, 20:376-383.
29. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084.
30. Foster N.F., Collins D.A., Ditchburn S.L., Duncan C.N., van Schalkwyk J.W., Golledge C.L., et al. Epidemiology of Clostridium difficile infection in two tertiary-care hospitals in Perth, Western Australia: a cross-sectional study. New Microbes New Infect. 2014, 2:64-71.
31. Lee J.H., Lee Y., Lee K., Riley T.V., Kim H. The changes of PCR ribotype and antimicrobial resistance of Clostridium difficile in a tertiary care hospital over 10 years. J.Med. Microbiol. 2014, 63:819-823.
32. Sathyendran V., McAuliffe G.N., Swager T., Freeman J.T., Taylor S.L., Roberts S.A. Clostridium difficile as a cause of healthcare-associated diarrhoea among children in Auckland, New Zealand: clinical and molecular epidemiology. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33:1741-1747.
33. Akerlund T., Persson I., Unemo M., Noren T., Svenungsson B., Wullt M., et al. Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. J.Clin. Microbiol. 2008, 46:1530-1533.
34. Burns D.A., Heeg D., Cartman S.T., Minton N.P. Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. PLoS One 2011, 6:e24894.
35. Reeves A.E., Koenigsknecht M.J., Bergin I.L., Young V.B. Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect. Immun. 2012, 80:3786-3794.